Laleh Amiri-Kordestani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laleh Amiri-Kordestani has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
- Richard Pazdur
Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD
86 shared publications - Daniel L. Suzman
U.S. Food and Drug Administration 1 Center for Drug Evaluation and Research Silver Spring, Maryland
78 shared publications - Shenghui Tang
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
78 shared publications - Paul G. Kluetz
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
72 shared publications - Elaine Chang
U.S. Food and Drug Administration 1 Center for Drug Evaluation and Research Silver Spring, Maryland
67 shared publications - Chana Weinstock
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
64 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Figure S1 shows patient disposition in BLC3001
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Figure S1 shows patient disposition in BLC3001
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Figure S2 shows the distribution of erdafitinib doses received over time in BLC3001 Cohort 1
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Figure S2 shows the distribution of erdafitinib doses received over time in BLC3001 Cohort 1
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Data from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
On January 19, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to erdafitinib for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Substantial evidence of effectiveness was obtained from BLC3001 (THOR, NCT03390504) Cohort 1, which was an open-label trial in which 266 patients with FGFR3-altered la/mUC were randomized 1:1 to receive erdafitinib (8 mg once daily with potential uptitration to 9 mg) compared with chemotherapy (docetaxel 75 mg/m2 every 3 weeks or vinflunine 320 mg/m2 every 3 weeks) until disease progression or unacceptable toxicity. The primary endpoint was overall survival (OS). Statistically significant improvements in OS, progression-free survival, and objective response rate were demonstrated for erdafitinib compared with chemotherapy. The median OS was 12.1 months [95% confidence interval (CI), 10.3–16.4] in the erdafitinib arm and 7.8 months (95% CI, 6.5–11.1) in the chemotherapy arm [hazard ratio (HR), 0.64; 95% CI, 0.47–0.88; P = 0.0050]. Based on BLC3001 Cohort 2 results showing no OS benefit of erdafitinib compared with pembrolizumab (HR, 1.18; 95% CI, 0.92–1.51), the approval includes a limitation of use: Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-(L)1 inhibitor therapy. This article summarizes the data and the FDA thought process supporting the traditional approval of erdafitinib, including the rationale for not requiring specific types of prior systemic therapy in the indication statement.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
On January 19, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to erdafitinib for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Substantial evidence of effectiveness was obtained from BLC3001 (THOR, NCT03390504) Cohort 1, which was an open-label trial in which 266 patients with FGFR3-altered la/mUC were randomized 1:1 to receive erdafitinib (8 mg once daily with potential uptitration to 9 mg) compared with chemotherapy (docetaxel 75 mg/m2 every 3 weeks or vinflunine 320 mg/m2 every 3 weeks) until disease progression or unacceptable toxicity. The primary endpoint was overall survival (OS). Statistically significant improvements in OS, progression-free survival, and objective response rate were demonstrated for erdafitinib compared with chemotherapy. The median OS was 12.1 months [95% confidence interval (CI), 10.3–16.4] in the erdafitinib arm and 7.8 months (95% CI, 6.5–11.1) in the chemotherapy arm [hazard ratio (HR), 0.64; 95% CI, 0.47–0.88; P = 0.0050]. Based on BLC3001 Cohort 2 results showing no OS benefit of erdafitinib compared with pembrolizumab (HR, 1.18; 95% CI, 0.92–1.51), the approval includes a limitation of use: Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-(L)1 inhibitor therapy. This article summarizes the data and the FDA thought process supporting the traditional approval of erdafitinib, including the rationale for not requiring specific types of prior systemic therapy in the indication statement.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Table S1 summarizes molecular alterations in BLC3001 Cohort 1 in more detail than what is provided in the baseline characteristics table included in the main text (Table 2)
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Table S1 summarizes molecular alterations in BLC3001 Cohort 1 in more detail than what is provided in the baseline characteristics table included in the main text (Table 2)
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Table S2 summarizes exposure and safety data for the safety population (treated patients) in BLC 3001 Cohort 1
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Table S2 summarizes exposure and safety data for the safety population (treated patients) in BLC 3001 Cohort 1
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Table S3 summarizes objective response rates in BLC3001 Cohort 1, BLC3001 Cohort 2, and BLC2001
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Table S3 summarizes objective response rates in BLC3001 Cohort 1, BLC3001 Cohort 2, and BLC2001
- 12 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4519-4524
FDA Approval Summary: Erdafitinib for FGFR3 -Altered Locally Advanced or Metastatic Urothelial Carcinoma
On January 19, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to erdafitinib for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Substantial evidence of effectiveness was obtained from BLC3001 (THOR, NCT03390504) Cohort 1, which was an open-label trial in which 266 patients with FGFR3-altered la/mUC were randomized 1:1 to receive erdafitinib (8 mg once daily with potential uptitration to 9 mg) compared with chemotherapy (docetaxel 75 mg/m2 every 3 weeks or vinflunine 320 mg/m2 every 3 weeks) until disease progression or unacceptable toxicity. The primary endpoint was overall survival (OS). Statistically significant improvements in OS, progression-free survival, and objective response rate were demonstrated for erdafitinib compared with chemotherapy. The median OS was 12.1 months [95% confidence interval (CI), 10.3–16.4] in the erdafitinib arm and 7.8 months (95% CI, 6.5–11.1) in the chemotherapy arm [hazard ratio (HR), 0.64; 95% CI, 0.47–0.88; P = 0.0050]. Based on BLC3001 Cohort 2 results showing no OS benefit of erdafitinib compared with pembrolizumab (HR, 1.18; 95% CI, 0.92–1.51), the approval includes a limitation of use: Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-(L)1 inhibitor therapy. This article summarizes the data and the FDA thought process supporting the traditional approval of erdafitinib, including the rationale for not requiring specific types of prior systemic therapy in the indication statement.
- 12 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4519-4524
FDA Approval Summary: Erdafitinib for FGFR3 -Altered Locally Advanced or Metastatic Urothelial Carcinoma
On January 19, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to erdafitinib for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Substantial evidence of effectiveness was obtained from BLC3001 (THOR, NCT03390504) Cohort 1, which was an open-label trial in which 266 patients with FGFR3-altered la/mUC were randomized 1:1 to receive erdafitinib (8 mg once daily with potential uptitration to 9 mg) compared with chemotherapy (docetaxel 75 mg/m2 every 3 weeks or vinflunine 320 mg/m2 every 3 weeks) until disease progression or unacceptable toxicity. The primary endpoint was overall survival (OS). Statistically significant improvements in OS, progression-free survival, and objective response rate were demonstrated for erdafitinib compared with chemotherapy. The median OS was 12.1 months [95% confidence interval (CI), 10.3–16.4] in the erdafitinib arm and 7.8 months (95% CI, 6.5–11.1) in the chemotherapy arm [hazard ratio (HR), 0.64; 95% CI, 0.47–0.88; P = 0.0050]. Based on BLC3001 Cohort 2 results showing no OS benefit of erdafitinib compared with pembrolizumab (HR, 1.18; 95% CI, 0.92–1.51), the approval includes a limitation of use: Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-(L)1 inhibitor therapy. This article summarizes the data and the FDA thought process supporting the traditional approval of erdafitinib, including the rationale for not requiring specific types of prior systemic therapy in the indication statement.
- 10 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (20) , 1865-1868
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
- 10 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (20) , 1865-1868
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer
On March 28, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy (RC), for adults with muscle-invasive bladder cancer (MIBC). Substantial evidence of effectiveness was obtained from NIAGARA (NCT03732677), a randomized, phase III, open-label trial in cisplatin-eligible patients with MIBC who had not received prior systemic chemotherapy or immunotherapy. A total of 1,063 patients were randomized (1:1) to receive neoadjuvant durvalumab + gemcitabine and cisplatin prior to RC, followed by adjuvant durvalumab (GC-D), or neoadjuvant gemcitabine and cisplatin (GC) prior to RC, with no subsequent adjuvant treatment. The dual primary endpoints were event-free survival (EFS) and pathologic complete response (pCR), both per blinded independent central review. The key secondary endpoint (α-controlled) was overall survival (OS). GC-D demonstrated a statistically significant improvement in EFS compared with GC at the second interim analysis, with a hazard ratio (HR) of 0.68 [95% confidence interval (CI), 0.56–0.82; P < 0.0001]. The median EFS was not reached (NR) for GC-D and was estimated to be 46.1 months (95% CI, 32.3–NR) for GC. There was no statistically significant difference in the pCR rate between the arms. A statistically significant improvement in OS was observed for GC-D compared with G + C, with an HR of 0.75 (95% CI, 0.59–0.93; two-sided P = 0.0106). The median OS was NR in both arms. Safety seemed consistent with the safety profile demonstrated in prior trials of durvalumab in combination with platinum-based chemotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer
On March 28, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy (RC), for adults with muscle-invasive bladder cancer (MIBC). Substantial evidence of effectiveness was obtained from NIAGARA (NCT03732677), a randomized, phase III, open-label trial in cisplatin-eligible patients with MIBC who had not received prior systemic chemotherapy or immunotherapy. A total of 1,063 patients were randomized (1:1) to receive neoadjuvant durvalumab + gemcitabine and cisplatin prior to RC, followed by adjuvant durvalumab (GC-D), or neoadjuvant gemcitabine and cisplatin (GC) prior to RC, with no subsequent adjuvant treatment. The dual primary endpoints were event-free survival (EFS) and pathologic complete response (pCR), both per blinded independent central review. The key secondary endpoint (α-controlled) was overall survival (OS). GC-D demonstrated a statistically significant improvement in EFS compared with GC at the second interim analysis, with a hazard ratio (HR) of 0.68 [95% confidence interval (CI), 0.56–0.82; P < 0.0001]. The median EFS was not reached (NR) for GC-D and was estimated to be 46.1 months (95% CI, 32.3–NR) for GC. There was no statistically significant difference in the pCR rate between the arms. A statistically significant improvement in OS was observed for GC-D compared with G + C, with an HR of 0.75 (95% CI, 0.59–0.93; two-sided P = 0.0106). The median OS was NR in both arms. Safety seemed consistent with the safety profile demonstrated in prior trials of durvalumab in combination with platinum-based chemotherapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
Table S3 shows incidence of new peripheral neuropathy over time in patients receiving combination treatment in EV-103
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
Table S3 shows incidence of new peripheral neuropathy over time in patients receiving combination treatment in EV-103